A detailed history of Galvin, Gaustad & Stein, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Galvin, Gaustad & Stein, LLC holds 3,470 shares of ABBV stock, worth $674,151. This represents 0.06% of its overall portfolio holdings.

Number of Shares
3,470
Previous 3,454 0.46%
Holding current value
$674,151
Previous $628,000 5.25%
% of portfolio
0.06%
Previous 0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 17, 2024

BUY
$154.79 - $180.76 $2,476 - $2,892
16 Added 0.46%
3,470 $595,000
Q1 2024

Apr 15, 2024

SELL
$159.82 - $182.1 $11,027 - $12,564
-69 Reduced 1.96%
3,454 $628,000
Q4 2023

Jan 11, 2024

SELL
$137.6 - $154.97 $57,654 - $64,932
-419 Reduced 10.63%
3,523 $545,000
Q3 2023

Oct 18, 2023

SELL
$133.59 - $154.65 $12.9 Million - $15 Million
-96,897 Reduced 96.09%
3,942 $587,000
Q2 2023

Jul 24, 2023

SELL
$132.51 - $164.9 $1.27 Million - $1.59 Million
-9,619 Reduced 8.71%
100,839 $13.6 Million
Q1 2023

Apr 17, 2023

SELL
$144.61 - $166.54 $266,371 - $306,766
-1,842 Reduced 1.64%
110,458 $17.6 Million
Q4 2022

Feb 13, 2023

BUY
$138.31 - $165.87 $878,545 - $1.05 Million
6,352 Added 6.0%
112,300 $18.2 Million
Q3 2022

Oct 26, 2022

SELL
$134.21 - $153.93 $777,881 - $892,178
-5,796 Reduced 5.19%
105,948 $14.2 Million
Q2 2022

Jul 22, 2022

SELL
$137.62 - $174.96 $2.38 Million - $3.02 Million
-17,273 Reduced 13.39%
111,744 $17.1 Million
Q1 2022

Apr 27, 2022

SELL
$131.98 - $163.75 $3.19 Million - $3.96 Million
-24,162 Reduced 15.77%
129,017 $20.9 Million
Q4 2021

Jan 31, 2022

SELL
$107.43 - $135.93 $1.09 Million - $1.37 Million
-10,115 Reduced 6.19%
153,179 $20.7 Million
Q3 2021

Oct 29, 2021

BUY
$106.4 - $120.78 $17.4 Million - $19.7 Million
163,294 New
163,294 $17.6 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $344B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Galvin, Gaustad & Stein, LLC Portfolio

Follow Galvin, Gaustad & Stein, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Galvin, Gaustad & Stein, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Galvin, Gaustad & Stein, LLC with notifications on news.